Literature DB >> 28755388

Killer-cell immunoglobulin-like receptors on the cusp of modern immunogenetics.

Francesco Colucci1,2, James Traherne3.   

Abstract

Killer-cell immunoglobulin-like receptors (KIR) and their human leukocyte antigen (HLA) ligands play a central role in immunity and human health. These molecules are encoded by gene families with copy number variation, extreme levels of sequence diversity and complex expression patterns. The rapid evolution of KIR and HLA genes and their associations with infectious diseases, pregnancy disorders, immunopathologies and outcome of cell transplantation have generated considerable interest from immunologists, geneticists and clinicians. Until recently, however, analyses have been stuck at low-level resolution, focusing primarily on presence or absence of KIR genes. This is changing with the advent of modern high throughput sequencing, cell phenotyping and bioinformatics. These developments allow high-resolution analysis and much deeper understanding of KIR evolution and KIR function. The impending deluge of high dimensional data brings inevitably new challenges in analysis, interpretation and communication of results, but the benefits are already tangible. The diversity of KIR across worldwide human populations is being catalogued at the allele level. Structures of KIR molecules and their interactions with HLA-peptide complexes are being determined. How KIR modulate natural killer cell education is being defined. Ligands for activating KIR, elusive for many years, are being discovered. KIR gene complexes and their related receptor gene families are being characterized in animal models and livestock breeds. These advances are helping to generate a more complete picture of the impact of KIR variation in health and disease and offer new opportunities for immunotherapy, as highlighted in a recent meeting (The Tenth KIR Workshop, April 2017 Cambridge, UK).
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Genomics; Killer-cell immunoglobulin-like receptors; MHC/HLA; natural killer cell

Mesh:

Substances:

Year:  2017        PMID: 28755388      PMCID: PMC5680062          DOI: 10.1111/imm.12802

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

1.  HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells.

Authors:  Christian Körner; Camille R Simoneau; Philipp Schommers; Mitchell Granoff; Maja Ziegler; Angelique Hölzemer; Sebastian Lunemann; Janet Chukwukelu; Björn Corleis; Vivek Naranbhai; Douglas S Kwon; Eileen P Scully; Stephanie Jost; Frank Kirchhoff; Mary Carrington; Marcus Altfeld
Journal:  Cell Host Microbe       Date:  2017-07-12       Impact factor: 21.023

2.  Defining KIR and HLA Class I Genotypes at Highest Resolution via High-Throughput Sequencing.

Authors:  Paul J Norman; Jill A Hollenbach; Neda Nemat-Gorgani; Wesley M Marin; Steven J Norberg; Elham Ashouri; Jyothi Jayaraman; Emily E Wroblewski; John Trowsdale; Raja Rajalingam; Jorge R Oksenberg; Jacques Chiaroni; Lisbeth A Guethlein; James A Traherne; Mostafa Ronaghi; Peter Parham
Journal:  Am J Hum Genet       Date:  2016-08-04       Impact factor: 11.025

3.  Inhibitory 2B4 contributes to NK cell education and immunological derangements in XLP1 patients.

Authors:  Raffaella Meazza; Michela Falco; Stefania Marcenaro; Fabrizio Loiacono; Paolo Canevali; Francesca Bellora; Claudia Tuberosa; Franco Locatelli; Concetta Micalizzi; Alessandro Moretta; Maria C Mingari; Lorenzo Moretta; Maurizio Aricò; Cristina Bottino; Daniela Pende
Journal:  Eur J Immunol       Date:  2017-05-05       Impact factor: 5.532

Review 4.  Diversification of both KIR and NKG2 natural killer cell receptor genes in macaques - implications for highly complex MHC-dependent regulation of natural killer cells.

Authors:  Lutz Walter; Beatrix Petersen
Journal:  Immunology       Date:  2016-10-05       Impact factor: 7.397

5.  Activating KIR2DS4 Is Expressed by Uterine NK Cells and Contributes to Successful Pregnancy.

Authors:  Philippa R Kennedy; Olympe Chazara; Lucy Gardner; Martin A Ivarsson; Lydia E Farrell; Shiqiu Xiong; Susan E Hiby; Francesco Colucci; Andrew M Sharkey; Ashley Moffett
Journal:  J Immunol       Date:  2016-11-04       Impact factor: 5.422

6.  Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.

Authors:  E Bernson; A Hallner; F E Sander; O Wilsson; O Werlenius; A Rydström; R Kiffin; M Brune; R Foà; J Aurelius; A Martner; K Hellstrand; F B Thorén
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

7.  Modulation of Human Leukocyte Antigen-C by Human Cytomegalovirus Stimulates KIR2DS1 Recognition by Natural Killer Cells.

Authors:  Kattria van der Ploeg; Chiwen Chang; Martin A Ivarsson; Ashley Moffett; Mark R Wills; John Trowsdale
Journal:  Front Immunol       Date:  2017-03-29       Impact factor: 7.561

8.  2.7 million samples genotyped for HLA by next generation sequencing: lessons learned.

Authors:  Gerhard Schöfl; Kathrin Lang; Philipp Quenzel; Irina Böhme; Jürgen Sauter; Jan A Hofmann; Julia Pingel; Alexander H Schmidt; Vinzenz Lange
Journal:  BMC Genomics       Date:  2017-02-14       Impact factor: 3.969

9.  Tissue-Specific Education of Decidual NK Cells.

Authors:  Andrew M Sharkey; Shiqiu Xiong; Philippa R Kennedy; Lucy Gardner; Lydia E Farrell; Olympe Chazara; Martin A Ivarsson; Susan E Hiby; Francesco Colucci; Ashley Moffett
Journal:  J Immunol       Date:  2015-08-28       Impact factor: 5.422

10.  Reproduction, infection and killer-cell immunoglobulin-like receptor haplotype evolution.

Authors:  Bridget S Penman; Ashley Moffett; Olympe Chazara; Sunetra Gupta; Peter Parham
Journal:  Immunogenetics       Date:  2016-08-12       Impact factor: 2.846

View more
  7 in total

1.  Natural killer cell transcriptional control, subsets, receptors and effector function.

Authors:  Daniel M Altmann
Journal:  Immunology       Date:  2019-02       Impact factor: 7.397

2.  Bioinformatics for immunologists.

Authors:  Daniel M Altmann
Journal:  Immunology       Date:  2018-09       Impact factor: 7.397

3.  The Presence of HLA-A Bw4-80I KIR Ligands Could Predict "Difficult-to-Treat" Psoriasis and Poor Response to Etanercept.

Authors:  M Guarene; A Pasi; V Bolcato; R Cananzi; A Piccolo; I Sbarsi; C Klersy; R Cacciatore; Valeria Brazzelli
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

4.  Lack of association of the KIR and HLA class I ligands with ZIKV infection in south and southeast of Brazil.

Authors:  Laise Nayana Sala Elpidio; Amarilis Giaretta de Moraes; Ieda Bernadete Volkweis Langer; Greicy Cezar do Amaral; Maria Luiza Moretti; Márcia Teixeira Garcia; Rodrigo Angerami; José Luiz Proenca-Modena; Karina Bispo-Dos-Santos; Matheus Cavalheiro Martini; Pierina Lorencini Parise; Christiane Maria Ayo; Luiz Carlos de Mattos; Cinara Cássia Brandão; Maurício Lacerda Nogueira; Denise Cristina Mós Vaz Oliani; Lígia Cosentino Junqueira Franco Spegiorin; Quirino Alves de Lima Neto; Jeane Eliete Laguila Visentainer
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-08-15       Impact factor: 2.747

Review 5.  Variations in killer-cell immunoglobulin-like receptor and human leukocyte antigen genes and immunity to malaria.

Authors:  Stephen Tukwasibwe; Annettee Nakimuli; James Traherne; Olympe Chazara; Jyothi Jayaraman; John Trowsdale; Ashley Moffett; Prasanna Jagannathan; Philip J Rosenthal; Stephen Cose; Francesco Colucci
Journal:  Cell Mol Immunol       Date:  2020-06-15       Impact factor: 11.530

6.  Decidual Vasculopathy in Preeclampsia and Spiral Artery Remodeling Revisited: Shallow Invasion versus Failure of Involution.

Authors:  Peilin Zhang
Journal:  AJP Rep       Date:  2018-10-18

7.  Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.

Authors:  Guoxu Zheng; Zhangyan Guo; Weimiao Li; Wenjin Xi; Baile Zuo; Rui Zhang; Weihong Wen; An-Gang Yang; Lintao Jia
Journal:  Signal Transduct Target Ther       Date:  2021-06-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.